|
Company data displayed is for sample purposes only and may not reflect the most current information available on Emerging Markets Information Service (EMIS).
DAEWON PHARMACEUTICAL CO.,LTD.
Main Activities: Pharmaceutical and Medicine Manufacturing
 |
Please check the full coverage of information what EMIS can offer you. | SEE SAMPLE |
Company Information |
|
Full name DAEWON PHARMACEUTICAL CO.,LTD. Headquarters 229-3, YONGDAP-DONG, SEONGDONG-GU, SEOUL; Seoul; Seoul; 143838 |
Status: Listed Legal Form: Public Limited Company Operational Status: Operational Financial Auditors: KPMG (2011) Incorporation Date: August 9, 1961 Total Employees: 523 Tel: 02-2204-7000 |
|
Company Description |
| Sales slightly decreased with main products sales hit by government regulation such as dual punishment system for rebate.Profitability slightly decreased from the year-earlier period with increasing cost burden for outsourcing and processing despite reduced marketing expense.It advanced into the medical appliance industry by incorporating hearing aid manufacturer Delight Co., Ltd.In April 2011. Sales will be recovered with new income sources from the medical appliance industry (hearing aid) with | ||
|
||
Company Analysis |
| According to the Individual - Audited financial statement for the first half of 2012, total net operating revenues decreased with -6.20%, from KRW 68,957,821 thousands to KRW 64,680,601 thousands. Operating result decreased from KRW 9,723,577 thousands to KRW 5,370,010 thousands which means -44.77% change. The results of the period decreased -40.43% reaching KRW 3,821,204 thousands at the end of the period against KRW 6,414,894 thousands last year. Return on equity (Net income/Total equity) went from 6.35% to 3.56%, the Return On Asset (Net income / Total Asset) went from 4.77% to 2.65% and the Net Profit Margin (Net Income/Net Sales) went from 9.30% to 5.91% when compared to the same period of last year. The Debt to Equity Ratio (Total Liabilities/Equity) was 34.54% compared to 33.10% of last year. Finally, the Current Ratio (Current Assets/Current Liabilities) went from 2.72 to 2.71 when compared to the previous year. |
Key Executives |
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
Companies with Similar Main Activities |
FULL COMPANY PROFILE
|
|
2012 H1 (non-cons) |
2011 Y (non-cons) |
|
 | ||
| Audited | Audited | |
| ||
| KR listed company financials | KR listed company financials | |
| ||
| Unit | Thousands | Thousands |
| ||
Balance Sheet
| ||
Total Assets |
144,430,255 |
139,669,778 |
| ||
Current Assets |
71,303,937 |
67,212,586 |
| ||
Total Liabilities |
37,079,132 |
35,665,687 |
| ||
Shareholders Equity |
107,351,123 |
104,004,091 |
| ||
Current Liabilities |
26,349,318 |
24,927,555 |
| ||
| * All the accounts are in KRW. | ||
Income Statement
| ||
Total Operating Revenue |
64,680,601 |
137,929,016 |
| ||
Operational Profit (Loss) |
5,370,010 |
14,507,495 |
| ||
Net Profit (Loss) |
3,821,204 |
9,705,519 |
| ||
| * All the accounts are in KRW. | ||
Ratios
| Profitability Ratios | ||
| ||
Return on Assets (ROA) |
2.65% |
6.95% |
| ||
Return on Equity (ROE) |
3.56% |
9.33% |
| ||
Return on Sales (ROS) |
5.91% |
7.04% |
| ||
Return on Capital |
3.24% |
8.46% |
| ||
Gross Profit Margin |
52.65% |
55.89% |
| Efficiency Ratios | ||
| ||
Current asset turnover |
0.91x |
2.05x |
| ||
Asset Turnover |
0.45x |
0.99x |
| Valuation figures and ratios | ||
| ||
Earning Before Interests and Taxes (EBIT) |
2,151,300 |
6,151,024 |
| ||
EBITDA |
5,761,752 |
15,245,525 |
| ||
Bookvalue (BV) |
98,413,880 |
94,864,546 |
| Liquidity Ratios | ||
| ||
Current Ratio |
270.61% |
269.63% |
| ||
Quick ratio |
211.3% |
210.47% |
| ||
Doom's day ratio |
93.31% |
67.86% |
| ||
Cash Flow to Debt |
20.69% |
4.94% |
| Leverage Ratios | ||
| ||
Leverage ratio |
134.54% |
134.29% |
| ||
Interest Coverage Ratio |
4,206.36% |
4,696.5% |
| ||
Debt to equity |
34.54% |
34.29% |
| ||
Debt to total assets |
25.67% |
25.54% |
| ||
Long Term Debt to Capital |
9.09% |
9.36% |
| Market ratios | ||
| ||
Price/Book Ratio |
0.60 |
0.62 |
| Trend Ratios | ||
| ||
Revenue Trend |
93.8% |
95.32% |
| ||
Net Income Trend |
59.57% |
81.93% |
| ||
 |